跳至主要内容
临床试验/NCT00452179
NCT00452179已完成2 期

A Randomized, Double-Blind, Placebo-Controlled, 3-Way Cross-Over Study to Evaluate the Effects of APD125 in Patients With Chronic Primary Insomnia

Arena Pharmaceuticals1 个研究点 分布在 1 个国家目标入组 173 人开始时间: 2007年2月最近更新:
适应症
相关药物

试验速览

阶段
2 期
状态
已完成
发起方
入组人数
173
试验地点
1
主要终点
Conventional PSG parameters

研究概览

简要总结

The purpose of this study is to determine the effects of APD125 in patients with sleep maintenance insomnia.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Treatment
盲法
Double

入排标准

年龄范围
18 Years 至 64 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Primary insomnia as defined in DSM-IV-TR, with predominant complaint of impaired sleep maintenance and confirmed by PSG
  • PSQI >/= to 5
  • Qualifying screening PSG parameters
  • Generally good health

排除标准

  • History of any sleep disorder, other than primary insomnia (e.g., restless leg syndrome, narcolepsy, sleep apnea, and disorders of REM/NREM sleep)
  • Any clinically significant medical condition, laboratory finding, or ECG finding
  • Pregnant and/or lactating females
  • History of substance abuse within 2 years or positive urine drug screen
  • Positive Hepatitis B/C results or HIV markers
  • Apnea-Hypopnea Index (AHI) or a Periodic Limb Movement Arousal Index (PLMAI) > 10 as determined by screening PSG
  • History of treatment with an investigational drug within the last month
  • Recent travel involving crossing more than 3 time zones or plans to travel to another time zone (> 3 time zones) during the study

结局指标

主要结局

Conventional PSG parameters

次要结局

  • Patient reported subjective sleep parameters

研究者

发起方
Arena Pharmaceuticals
申办方类型
Industry

研究点 (1)

Loading locations...

相似试验